Wells Fargo
NAMS icon

Wells Fargo’s NewAmsterdam Pharma NAMS Stock Holding History

Wells Fargo’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$611K Buy
18,038
+17,138
+1,904% +$565K ﹤0.01% 4478
2026
Q1 		$28.8K Hold
900
– – ﹤0.01% 5647
2025
Q4 		$31.6K Buy
900
+300
+50% +$10.9K ﹤0.01% 5679
2025
Q3 		$17.1K Buy
600
+400
+200% +$9.59K ﹤0.01% 5833
2025
Q2 		$3.62K Sell
200
-300
-60% -$5.47K ﹤0.01% 6135
2025
Q1 		$10.2K Hold
500
– – ﹤0.01% 5879
2024
Q4 		$12.8K Hold
500
– – ﹤0.01% 5877
2024
Q3 		$8.3K Hold
500
– – ﹤0.01% 5840
2024
Q2 		$9.61K Hold
500
– – ﹤0.01% 5754
2024
Q1 		$11.8K Buy
500
+200
+67% +$4.06K ﹤0.01% 5711
2023
Q4 		$3.35K Hold
300
– – ﹤0.01% 6019
2023
Q3 		$2.77K Hold
300
– – ﹤0.01% 6047
2023
Q2 		$3.57K Buy
+300
New +$3.98K ﹤0.01% 6126

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
DFO
Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

Wells Fargo's NAMS Position: Q2 2026 in Review

Wells Fargo increased its NewAmsterdam Pharma (NAMS) stake by 1,904% in Q2 2026, buying an estimated $565K and bringing the position to 18,038 shares worth $611K. The position accounts for ﹤0.01% of the portfolio, ranked #4478.

Wells Fargo first reported a position in NAMS in Q2 2023 and has held it in 13 quarters since. 194 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

  • Wells Fargo held 18,038 shares of NewAmsterdam Pharma worth $611K as of Q2 2026.
  • Wells Fargo bought 17,138 NewAmsterdam Pharma shares in Q2 2026, an estimated $565K.
  • NewAmsterdam Pharma made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #4478 holding.
  • Wells Fargo first reported a position in NewAmsterdam Pharma in Q2 2023 and has held it in 13 quarters since.
  • 194 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.